UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2022

DARÉ BIOSCIENCE, INC. (Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823 (I.R.S. Employer Identification No.)

(State or other jurisdiction of incorporation)

(Commission File Number)

3655 Nobel Drive, Suite 260

San Diego, CA 92122 (Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: (858) 926-7655

Not Applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Common stock

Trading Symbol(s) DARE

Name of each exchange on which registered Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

Included as Exhibit 99.1 to this report is a presentation about Daré Bioscience, Inc. ("Daré") and its product candidates, dated March 7, 2022, which is incorporated herein by reference. Daré intends to use the presentation and its contents in various meetings with investors, securities analysts and others, commencing on March 7, 2022.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate presentation, dated March 7, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 7, 2022


DARÉ BIOSCIENCE, INC.

By: Name: Title: /s/ Sabrina Martucci Johnson Sabrina Martucci Johnson President and Chief Executive Officer

Exhibit 99.1

darébio

Daré Bioscience






DARÉ IN ITALIAN, IT MEANS "TO GIVE." IN ENGLISH, IT MEANS "TO BE BOLD."

......

NASDAQ: DARE www.darebioscience.com

Corporate Presentation: March 7, 2022

©2022 Daré Bioscience | All rights reserved



Women's Health is Our Sole Focus

Daré Bioscience is a biopharmaceutical company committed to addressing the lack of innovation in women's health primarily in the areas of contraception, fertility, and vaginal and sexual health.

- We work to accelerate innovative product options in women's health that...
- Expand treatment options,
- Enhance outcomes, and
- Improve ease of use for women.



- We partner to...
- Drive innovation and develop new solutions,
- Accelerate novel products to address persistent unmet needs in a time and capital efficient manner, and
- Become a pipeline resource for large and emerging commercial companies.

We look for differentiated investigational products with...

Attractive market opportunities + unmet medical needs,

Prior human proof-of-concept and/or ability to leverage a 505(b)(2) regulatory pathway,


First-in-category or first-line potential, and

Opportunity to personalize for women with novel, convenient routes of administration.


Compar	ny Highlights	Program Milestones* 2022
1	Diverse pipeline with independent outcomes One FDA-approved product and several clinical development stage candidates utilizing different APIs and targeting different indications	XACIATO TM (clindamycin phosphate) vaginal gel, 2% (f/k) DARE-BV1) (bacterial vaginosis) • Partnership agreement
2	Multiple novel delivery platforms Persistent unmet needs require creative new approaches designed for her	 U.S. commercial launch Ovaprene® (hormone-free monthly contraception) IDE clearance Pivotal Phase 3 study commence
3	Meaningful market potential First-line or first-in-category product opportunities across the portfolio	DARE-VVA1 (vaginal atrophy treatment for women with breast cancer) • Phase 1/2 study topline data
4	505(b)(2) FDA pathway planned for most candidates Use of well-characterized APIs expected to mitigate development risk, time, and cost	 Sildenafil Cream, 3.6% (female sexual arousal disorder) Phase 2b study topline data target date announcement pending interim analysis for study sizing
5	Commercial value in women's health evidenced by recent transformational pharma transactions	

Advancing Products Women Want – The Portfolio Snapshot

0



Advancing Products Women Want – Late Stage Programs



^505(b)(2) regulatory pathway anticipated 1.https://www.cdc.gov/std/bv/stats.htm 6

0

darébio

.

.



PRODUCT CANDIDATE	PRE-CLINICAL	PHASE 1			
DARE-HRT1 [^] Hormone Therapy - Phase :	1 Study Completed	 First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days. Potential to be the first convenient monthly format product with both hormones. 			
DARE-FRT1/PTB1 [^] Pregnancy Maintenar	nce - Phase 1 Study Preparation	 First-in-category progesterone delivery for pregnancy maintenance including the prevention of preterm birth (DARE-PTB1) and for luteal phase support as part of an IVF regimen (DARE-FRT1). IVR designed to release bio-identical progesterone over 14 days. Alternative to daily IM injections or vaginal gel 			
DARE-VVA1 [^] Vulvar and Vaginal Atrophy	- Phase 1/2 Study Commenced	 First-in-category hormone-free vaginal treatment for vulvar and vaginal atrophy (VVA) in hormone-receptor positive (IR+) breast cancer patient population. Proprietary formulation of tamoxifen for vaginal administration. Potential to be the first therapeutic specifically approved for treatment of VVA in patients with HR+ breast cancer. 			
DARE-LARC1 [^] Long-Acting, Reversible F Contraceptive System	Personal	Levonorgestrel-releasing, long-acting contraceptive implant that a woman can turn on and off herself, according to her own needs. Grant of up to \$48.95 M to advance technology through non clinical proof of principle to enable IND submission, and an NIH grant to explore device insertion/removal in non-clinical studies.			
ADARE 204/214 [^] 6 & 12-Month Injectable Contraception		Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility.			
DARE-RH1 Male or Female Contraceptive Target		A potential new rapidly reversible, non-hormonal contraceptive solution with application for women and men.			
^sos(b)(2) regulatory pathway anticipated.					

2022 Near Term Catalysts to Drive Value

Milestones

XACIATO [™] Bacterial Vaginosis*	NDA approved December7, 2021	 XACIATO NDA approved December 7, 2021 Partnering discussions ongoing to support 2022 launch
DARE-VVA1 [^] Vulvar and Vaginal Atrophy	Phase 1/2 Study ongoing	DARE-VVA1 1. Phase 1/2 commenced 3Q2021 2. Topline Phase 1/2 data anticipated 2022
Ovaprene [®] Contraception	Pivotal Phase 3 Study commence	Ovaprene 1. IDE submission process ongoing 2. Pivotal study commence anticipated 2022
Sildenafil Cream, 3.6% [^] FSAD	Phase 2b Study ongoing	 Sildenafil Cream, 3.6% Phase 2b commenced 1Q2021 Topline Phase 2b data target date pending interim analysis for study sizing

*XACIATO is indicated for the treatment of bacterial vaginosis in females 12 years and older. See Full Prescribing Information.

^505(b)(2) regulatory pathway anticipated

Daré: Advancing Products Women Want



9

.

Experienced Management & Board of Directors

Managem	ent Team	Board of Directors	
Q	Sabrina Martucci Johnson MSc, MIM President & CEO	William Rastetter, PhD Chairman	Greg Matz, CPA
	John Fair Chief Strategy Officer	Cheryl Blanchard, PhD	Sophia N. Ononye-Onyia, PhD, MPH, MBA
	Lisa Walters-Hoffert Chief Financial Officer	Jessica Grossman, MD	Robin Steele, JD, LLM
	David Friend, PhD Chief Scientific Officer	Susan Kelley, MD	Sabrina Martucci Johnson MSc, MIM President & CEO
<u> </u>	Mary Jarosz, RPh, RAC, FTOPRA Global Head of Regulatory Affairs	Bankof America Bayer biogen idec Image: Constraint of the second	Alios ARQULE Baxter Hyers Squibb' O Calibre Memory CÎÎ C O N R A D
	Mark Walters Vice President of Operations	CooperCompanies Corress and Contraction GRAI	L merenden ilgenia illumina oliverimune come opennemer Epizer PACIRA Possian
R	Christine Mauck, MD, MPH Medical Director	i receptos @ коти Skyepharma SRI Into We are delivering innovation by	ternational LS FOOD & ORUG Wyeth Commence of the provide of the pr

10

XACIATO[™] (Clindamycin Phosphate) Vaginal Gel, 2% FDA approved for the treatment of bacterial vaginosis, the most common vaginal infection in women of reproductive age

Convenient, one-time intravaginal administration

NDA approved December 7, 2021

XACIATO is indicated for the treatment of bacterial vaginosis in females 12 years and older. See Full Prescribing Information for the safe and effective use of XACIATO.

Recurring infection, difficult to treat effectively

► Most common vaginal infection in women ages 15-44, affecting ~21 million women in the US¹

Current Rx suboptimal: clinical cure rates of 37-68%²

Bacterial Vaginosis increases health risk³

► Preterm birth – bacterial vaginosis is linked to premature deliveries, low birth weight babies

Sexually transmitted infections – bacterial vaginosis increases susceptibility to HIV, herpes simplex virus, chlamydia, gonorrhea

► Post-surgical infection – bacterial vaginosis may increase risk of infection after gynecologic procedures

► Pelvic inflammatory disease – bacterial vaginosis may cause PID, an infection that affects women's reproductive organs and can increase the risk of infertility

Bacterial vaginosis product data: http

prwww.accessaata.roa.gov/oroganroa_occanaber/2014/20522300000.pbi tps://www.mayoclinic.org/diseases-conditions/bacterial-vaginosis/symptoms-causes/syc-20352279

XACIATO: Overview

► XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosis.

► This marks the first FDA-approved product in Daré's portfolio of potential first-in-category development candidates.

Partnering discussions ongoing – **U.S. commercial launch expected 2022** Supply to support commercial launch expected earliest summer 2022.



NDA Approved December 7, 2021

XACIATO - A Difference in the Lives of Women

"The FDA approval of XACIATO marks a major milestone not only for Daré as a company but, importantly, for the 21 million women impacted by bacterial vaginosis," said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. "It is our goal as a company to accelerate the development of differentiated products that can improve outcomes and convenience for women. In the case of XACIATO, this FDA approval comes just three years after we licensed this technology. We are grateful to the FDA for their thoughtful review and the alignment on labeling. We hope that this is the first of many FDA approvals in our efforts to improve the lives of women with treatment options that address some of the most persistent unmet needs."

"Bacterial vaginosis is not a sexually transmitted infection, but rather an overgrowth of bacteria naturally found in the vagina, which upsets the balance of the natural vaginal microbiome and leads to not only distressing symptoms of odor and discharge, but also increases a woman's risk of preterm birth, infertility, and infections. Today, approximately half of the women treated for bacterial vaginosis experience a recurrence within 12 months of treatment. There is a need for more efficacious and convenient treatment options, particularly products with improved clinical outcomes for not only the newly diagnosed women, but, importantly, also for the women who experience multiple episodes of bacterial vaginosis each year," said David Friend, Ph.D., Daré's Chief Scientific Officer. "Now that we have achieved this important demonstration of this drug delivery hydrogel platform technology, we are actively exploring the opportunity to leverage it across other unmet needs in women's health."

14

1. https://ir.darebioscience.com/news-releases/news-release-details/dare-announces-fda-approval-xaciatotm-clindamycin-phosphate

XACIATO: Important Safety Information Important Safety Information*: Indication: XACIATO (clindamycin phosphate) vaginal gel is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. Dosage and Administration: Administer one applicatorful (5 g of gel containing 100 mg of clindamycin) once intravaginally as a single dose at any time of the day. Not for ophthalmic, dermal, or oral use. Contraindications: XACIATO is contraindicated in patients with a history of hypersensitivity to clindamycin or lincomycin. Warnings and Precautions: • Clostridioides difficile-Associated Diarrhea (CDAD): Discontinue and evaluate if diarrhea occurs Use with Polyurethane Condoms: Polyurethane condoms are not recommended during treatment with XACIATO or for 7 days following treatment. During this time period, polyurethane condoms may not be reliable for preventing pregnancy or for protecting against transmission of HIV and other sexually transmitted diseases. Latex or polyisoprene condoms should be used. Adverse Reactions: The most common adverse reactions reported in >2% of patients in the Phase 3 placebo-controlled trial and at a higher rate in the XACIATO group than in the placebo group were vulvovaginal candidiasis and vulvovaginal discomfort. Drug Interactions: Systemic clindamycin has neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. It should be used with caution in patients receiving such agents. *See Full Prescribing Information at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215650s000lbl.pdf

XACIATO: Use in Specific Populations

Us	e in Specific Populations*:
•	Other clindamycin vaginal products have been used to treat pregnant women during the second and third trimester. XACIATO has not been studied in pregnant women. However, based on the low systemic absorption of XACIATO following the intravaginal route of administration in nonpregnant women, material use is not likely to result in significant fetal exposure to the drug.
•	Similarly, because systemic absorption following intravaginal administration of clindamycin is low, transfer of the drug into breastmilk is likely to be low and adverse effects on the breastfed infant are not expected.
•	The safety and effectiveness of XACIATO have not been established in pediatric patients younger than 12 years of age or in patients 65 years of age or older.
	Full Prescribing Information at: https://www.accessdata.fda.gov/drugsatfda.docs/label/2022/2166c05000lbl.pdf

16



Ovaprene® - Commercial License Agreement with Bayer¹

.

January 2020 - Bayer, which markets the \$1 billion Mirena contraceptive franchise, and Daré announced the execution of a license agreement under which Bayer may commercialize Ovaprene investigational contraceptive in the US once approved by FDA.



•Bayer received the right to obtain exclusive US rights to commercialize the product, following completion of the pivotal clinical trial if Bayer, in its sole discretion, pays Daré \$20 million.


•Daré may receive up to \$310 million in commercial milestone payments, plus double-digit, tiered royalties on net sales.

•Bayer supports the development and regulatory process by providing up to two full-time equivalents (internal experts) in an advisory capacity, which gives Daré access to their global manufacturing, regulatory, medical and commercial expertise.

We believe the licensing agreement with Bayer is validation of our broader corporate strategy and confirmation of Ovaprene's market potential, if approved, as the first monthly non-hormonal contraceptive product in the US market.


* https://www.mirena-us.com/; supported by 2014-2016 SHS data. 1.https://ir.darebioscience.com/news-releases/news-release-details/bayer-

Contraception: Large Market Opportunity




Ovaprene[®] - Potential Market Opportunity

There are approximately 65 million women in the US Aged 15-44¹



Contraception: What's Missing from Current Hormone-Free Options?



1.U.S. Food and Drug Administration Birth Control Guide dated 6/14/2021: https://www.fda.gov/consumers 2.U.S. Food and Drug Administration Drug Data Prescribing information for a vaganal gel approved in 2020. GigSk C1: 2069; 2099. Social org Cycles with back-up constractions, orgets-c2107-23 gdays in length and c2 https://www.accessdata.fda.gov/drugastfda_dozo/baleg2330000H.pdf TM provides that in a multicenter, o srovides that in a multicenter, open-label, single-arm clinical trial in the U.S. (AMPooz; NCTo3243305), the 7-cycle cumulative pregnancy rate was 33.7% ich no intercourse was reported. The estimated Pearl Index, calculated based on data from the 7-cycle study, was 27.5 (55% CI: 22.4%, 33.5%). 20. Phe 21

ear of typical use. Typical use shows how effective the different methods are during actual use (including sometimes using a method in a way that is not correct or not the risks of a specific product, please check the product label or Trussell, J. (2012). "Contraceptive failure in the United States." Contraception 83(5):397-404.

Ovaprene[®] Investigational Hormone-Free, Monthly Contraceptive

Physical Barrier ⁶	Desired Features of Birth Control Products: ²⁻⁴	Design Features of Ovaprene:57
Three-dimensional, knitted polymer barrier	+Efficacy	86% - 91% Expected Typical Use Effectiveness Approaching User-Controlled Hormone Contraception
	+Hormone Free	No Hormones in the API Unique dual action MOA (spermiostatic & barrier)
	+Convenience	Monthly Ring Form Women choose monthly intravaginal products for the convenience of a non-daily option
Spermiostatic Environment ⁶ Contraceptive-loaded silicone ring releasing non-hormonal active Ferrous	+Favorable Side Effect Profile	Safety Profile Similar to a Diaphragm No significant changes in vaginal flora and no serious adverse effects observed in studies to date
gluconate Inteps//www.urban.org/urban-wire/women-want-effective-birth-control I.terspt/, Urenprective on Secural and Reproductive Health, Volume 44, Number 3,9-7432 Hordorp DJ, Clin Magneting, 2019;02(13);05(5)	+Easily Manage Fertility	No Systemic/Long-term Activity Inserted and removed without a provider allowing for immediate return to fertility
4, Enel, J., Malen Child Health J (2021) 35,95-950 SphCT studies of similar size, products delarbarging that demonstrated no motile sperm in the cervical mucus d Reproduction, Volume Ion, Janes A, Augutt 2020, Reprod. 2024 Schamard Reproductive Medicine 2020, gcl 86:969 3, Tronsell J. Contraceptive Efficiancy. In Hather RA, Trousell J, Nelion AL, Cates W, Kowal D, Policar M. Contraceptive		veness of 86-gaN in pivotal contraceptive studies evaluating pregnancy rates oversix-month periods. Mauck C, Vincent K. Biology of 22 1.

Ovaprene[®] - U.S. Regulatory Strategy¹

Premarket approval (PMA) strategy – The Center for Devices and Radiological Health (CDRH) as lead review division

Step 1 (Completed)

•Postcoital Test (PCT) Clinical Study - Completed 4Q 2019

Step 2 (Ongoing)

1 - Obtain FDA clearance of investigational device exemption (IDE) to support 2022 pivotal study start.

2 - Conduct pivotal study

- ~200 subjects completing 12 months of use
- Primary endpoints: safety and efficacy (pregnancy probability)
- Secondary endpoints: acceptability, product fit/ease of use and assessments of vaginal health

Anticipated regulatory pathway and timelines.
 Mauck C., Vincent K. Biology of Reproduction, Volume 103, Issue 2, August 2020, Pages 437–444

The PCT Clinical Study Met its Primary Endpoint

Ovaprene prevented the requisite number of sperm from reaching the cervix across all women and all cycles evaluated.

•Specifically, in 100% of women and cycles, an average of less than five (< 5) progressively motile sperm (PMS) per high-powered field (HPF) were present in the midcycle cervical mucus collected two to three hours after intercourse with Ovaprene in place.

•Women enrolled in the study who completed at least one Ovaprene PCT (N=26) had a mean of 27.21 PMS/HPF in their baseline cycle (without any contraceptive device), a mean of o.22 PMS/HPF in their diaphragm cycle (in the presence of an FDA-cleared diaphragm with spermicide), and a mean of o.a8 PMS/HPF in their Ovaprene PCT cycles (in the presence of the Ovaprene device), with a median of zero PMS.

	Mean Progressively Motile Sperm	Median Progressively Motile Sperm	Standard Deviation	Interquartile Range
Baseline PCT's	27.21	23.20	17.88	24.80
Ovaprene PCT's	0.48	0.00	1.18	0.10

 In PCT studies of similar size, products (diaphragms) that demonstrated no motile sperm in the cervical mucus during PCT assessments later demonstrated "typical use" contraceptive effectiveness of 86-93% in pivotal contraceptive studies evaluating pregnancy rates over six-month periods.²

23



Ovaprene[®] - Collaborative Research Agreement with NIH¹

July 2021 – Daré announced that funding and clinical operations support for the Phase 3 will be provided by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Under the CRADA




Cooperative Research and Development Agreement (CRADA) for the Pivotal Phase 3 Study The pivotal Phase 3 study will be supported by the NICHD's Contraceptive Development Program which oversees the Contraceptive Clinical Trial Network (CCTN) established in 1996 to conduct studies of investigational contraceptives. The Phase 3 study will be conducted within the CCTN with the NICHD contractor Health Decisions Inc.

.


- Daré will be responsible for providing clinical supplies of Ovaprene[®] and coordinating interactions with and preparing and submitting supportive regulatory documentation to the FDA.
- Under the CRADA, Daré also agreed to contribute \$5.5 million toward the total estimated cost to conduct the pivotal Phase 3 study, payable in four payments. Two payments totaling \$1.5 million have been made in 2021.

"This collaboration between Daré and NICHD marks an important milestone in Women's Healthcare Innovation. Women are at the center of everything we do and we are so pleased to continue to partner with Daré in support of our mission We're For Her to provide women with education and access to contraceptive options, " said John Berrios, Bayer's Head of Women's Healthcare.

 ${\tt 1}, {\tt https://ir.darebioscience.com/news-releases/news-release-details/dare-announces-collaborative-research-agreement-crada-pivotal and the state of the s$



FSAD – The Clinical Issue



FSAD – What is the incidence?

Meta-analysis of 95 studies from 2000-2014 indicated prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 41%, and difficulty with arousal alone is 23%.¹

Market research estimates:

▶ 33% of US women aged 21 to 60

(~ 20 million women), experience symptoms of low or no sexual arousal.^{2,3}

► 10 million women are considered distressed and actively seeking treatment.²

McLooi et al. Sex Med Rev 2016;4:197-212.
 Ad Hoc Market Research: FSAD Prevalence



Sildenafil Cream, 3.6% - Product Profile

Topically administered investigational Sildenafil Cream¹ is...

► A PDE5 inhibitor utilized in ED medications for men – ED product Viagra® peaked at \$2.05 billion in sales in 2012.²

Designed to increase local blood flow to provide improvement in genital arousal response.

► Applied topically, avoiding hepatic first-pass metabolism response, resulting in lower systemic exposure potentially resulting in reduced side effects vs. oral sildenafil, including Viagra[®].

► Given **similarities between ED and FSAD**, sildenafil - the active ingredient in Viagra[®] - may improve genital arousal response and overall sexual experience for women as it does in men.

There are no FDA-approved treatments for FSAD

Sildenafil Cream, 3.6% - Phase 2b

Ongoing Phase 2b clinical study aims to evaluate Sildenafil Cream vs. placebo over 12 weeks of dosing following both a non-drug and placebo run-in period.


► Compares Sildenafil Cream vs. placebo used in patients' home setting.

► Primary endpoint: patient reported outcome (PRO) instruments to measure improvement in localized genital sensations of arousal and reduction in FSAD related distress.

Several exploratory efficacy endpoints will be measured and could become additional measurements of efficacy in a future Phase 3 program.



Oral Sildenafil provided a compelling proof of concept for FSAD



Key Takeaways of Viagra® studies:

.

•Increased blood flow and clinical efficacy observed with oral sildenafil (Viagra*) in women.

• The side effect profile of the oral formulation was not optimal for women - leading to the exploration of alternative delivery options including a topical route of administration.

1. The Enhancement of Vaginal Vasocongestion by Sildenafil in Healthy Premenopausal Women. Journal of Women's Health & Gender-Based Medicine. Vol. 11, No. 4. 2002 2. Safety and Efficacy of Sildenafil Citrate for the Treatment of FSAD: A Double-Blind, Placebo Controlled Study. The Journal of Urology. Vol 270, 2333-238, December 2003. 30

.

Sildenafil Cream, 3.6% - Phase 1 and Phase 2a Study Results

Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)¹ Normal healthy postmenopausal women were dosed with escalating doses of Sildenafil Cream, 3.6%, using a cross-over study design. Sildenafil Cream had significantly lower systemic exposure compared to a 50 mg oral sildenafil dose AUC – 3-6% C_{max} – 1-2% Sildenafil Cream was safe and well tolerated at clinically relevant doses (1-2g) Favorable product characteristics as self-reported by subjects Easy to use Readily absorbed

Phase 2a Study of SST-6007(Sildenafil Cream, 3.6%)¹


1. Data on file. Sildenafil Cream, 3.6% was previously known as SST-6007.

Demonstrated increased blood flow in the genital tissue compared to placebo (mean change in VPA analysis) in 31 women (pre and postmenopausal) ~30 minutes post dosing.



Treatment	N=59	Sildenafil Single Dose	C _{max} (ng/ml)	T _{max} (hr)	AUC _{last} (h*ng/ml)
Topical Sildenafil 1 g of cream	20	35 mg	3.4	2.37	25.6
Topical Sildenafil 2 g of cream	20	71 mg	3.8	2.27	30.8
Topical Sildenafil 4 g of cream	19	142 mg	5.3	2.22	42.5


Phase 1 Study



Sildenafil Cream, 3.6% - Thermography Study Results

Demonstrated time to effect (See Figure 1)

Figure 1. Clitoral temperature change during the sexually explicit film



Thermography Study Design & Methodology (N=6)¹

Phase 1, single-dose, double-blind, placebo-controlled, 2-way crossover study evaluating the feasibility of using thermography to assess the pharmacodynamics of Sildenafil Cream, 3.6% in normal healthy women. The study required 3 visits and a follow up contact: Visit 1 (screening), Visits 2-3 (double-blind dosing) and a phone call (safety follow-up).

1. Data on file.







Milestones and Catalysts

Daré – Working to Accelerate Innovation in Women's Health

2019 and 2020

- ✓ Positive findings of Sildenafil Cream, 3.6% thermography clinical study
- ✓ Positive topline data for Ovaprene® postcoital test clinical study
- ✓ Exclusive licensing agreement with Bayer for Ovaprene
- ✓ Strategic partnerships with Health Decisions / Avomeen
- ✓ Grant funding for DARE-LARC1 reaches \$20.5 million
- ✓ Positive topline data for DARE-BV1 Phase 3 study

2021

- ✓ Sildenafil Cream, 3.6% Phase 2b study commence
- ✓ DARE-HRT1 Phase 1 study positive topline data
- ✓ DARE-LARC1 grant of up to \$48.95 M awarded, \$11.45 M of which received
- ✓ Ovaprene CRADA with NICHD for Phase 3 Study providing non-dilutive cost-sharing and operational collaboration
- ✓ DARE-BV1NDA accepted for priority review by the FDA
- ✓ DARE-VVA1 Phase 1/2 study commence
- ✓ DARE-LARC1−NIH grant for \$309,000 awarded
- ✓ XACIATO (f/k/a DARE-BV1) NDA approval on December 7, 2021

Anticipated Milestones*

2022

XACIATO

- Commercial partnership
- U.S. commercial launch
- Ovaprene
- IDE clearance
- Pivotal Phase 3 study commence

DARE-VVA1

• Phase 1/2 study topline data

Sildenafil Cream, 3.6%

• Phase 2b study topline data target date announcement pending interim analysis for study sizing

*Currently anticipated timing 34

Phase 1 and Preclinical Programs

New investigational prescription drug delivery options for women



PRODUCT CANDIDATE	PRE-CLINICAL	PHASE 1		
DARE-HRT1 [^] Hormone Therapy - Phase 3	L Study Completed	 First-in-category combination hormone delivery for treatment of vasomotor and vaginal symptoms of menopause. Intravaginal ring (IVR) designed to release bio-identical estradiol and bio-identical progesterone over 28 days. Potential to be the first convenient monthly format product with both hormones. 		
DARE-FRT1/PTB1 [^] Pregnancy Maintenance - Phase 1 Study Preparation		 First-in-category progesterone delivery for pregnancy maintenance including the prevention of preterm birth (DARE-PTB1) and for luteal phase support as part of an IVF regimen (DARE-FRT). IVR designed to release bio-identical progesterone over 14 days. Alternative to daily IM injections or vaginal gel First-in-category hormone-free vaginal treatment for vulvar and vaginal atrophy (VVA) in hormone-receptor positive (HR+) breast cancer patient population. Proprietary formulation of tamoxifen for vaginal administration. Potential to be the first therapeutic specifically approved for treatment of VVA in patients with HR+ breast cancer. 		
DARE-VVA1 [^] Vulvarand Vaginal Atrophy – Phase 1/2 Study Commenced				
DARE-LARC1 [^] Long-Acting, Reversible F Contraceptive System	Personal	Levonorgestrel-releasing, long-acting contraceptive implant that a woman can turn on and off herself, according to her own needs. Grant of up to \$4,8.95 M to advance technology through non clinical proof of principle to enable IND submission, and an NIH grant to explore device insertion/removal in non-clinical studies.		
ADARE 204/214 [^] 6 & 12-Month Injectable Contraception		Novel 6 & 12-month injectable formulations of etonogestrel being developed as a longer-acting, reversible method of contraception with a more predictable return to fertility.		
DARE-RH1 Male or Female Contraceptive Target		A potential new rapidly reversible, non-hormonal contraceptive solution with application for women and men.		
^sos(b)(2) regulatory pathway anticipated.				

Intravaginal Ring (IVR) Technology Highlights

The Vaginal Route of Drug Administration¹

► Vaginal drug delivery offers many potential advantages due to large surface area, dense network of blood vessels and high elasticity due to presence of smooth muscle fibers.

► Recognized advantages include comparable ease of administration and ability to bypass hepatic first-pass metabolism. Our IVR Technology – Design Features:

► Sustained drug delivery,

► Variable dosing and duration,

► Solid ethylene vinyl acetate (EVA) polymer matrix that can contain and release one or several active drugs,

► No need for membrane or reservoir to contain active drug(s) or control the release.

DARE-HRT1

Combination bio-identical estradiol + bio-identical progesterone 28-day IVR for hormone therapy following menopause

45M women in U.S. approaching or in menopause¹

Hormone Therapy (HT)

HT remains the most effective treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM), and has been shown to prevent bone loss and fracture.²

•The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS), supports HT in peri-and post-menopausal women.²

NAMS observes: non-oral routes may offer advantages over oral routes of administration.²

Completed Phase 1 STUDY

A Phase 1, Open-Label, 3-arm Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 (80 μg and 160 μg Estradiol/ 4 mg and 8 mg Progesterone Intravaginal Rings) in Healthy Post-Menopausal Women.

The topline data from the study support DARE-HRT1's potential to be the first FDAapproved product to offer vaginal delivery of combination bio-identical estradiol and bio-identical progesterone hormone therapy in a convenient monthly format to treat both VMS as well as vaginal symptoms of menopause.

38

sos(b)(2) candidate? 10.5. Censor Bureau, Population Division. Table 2. 2015 to 2060 (NP2012-T2) 2.The 2017 hormone therapy position statement of therapy-position-statement pdf

ts for DARE-HRT1

DARE-FRT1 and DARE-PTB1

Bio-identical progesterone 14-day IVR for prevention of preterm birth and luteal phase support as part of an IVF treatment plan

Prevention of Preterm Birth (PTB)

After steadily declining from 2007 to 2014 3 , the US premature birth rate rose for the fourth straight year in 2018 with ~10% of babies born preterm (<37 weeks). 3

NIH Grant Funding for PTB Program

NIH

Potential for up to \$2.3 million in NIH grant funding to support DARE-PTB1 development •Notice of award for initial \$300,000 in grant funding announced Aug 2020. Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health Award Number R44 HD101169.

Assisted Reproductive Technologies (ART)/IVF

- As women wait longer to have children, infertility risk increases
- •~12-15% of couples cannot conceive after 1-year of unprotected sex.4

--20% of US women have their first child after age 35; -1/3 of couples in which the woman is older than 35 years have fertility problems. 5

505(b)(2) candidate¹

nticipated regulatory pathway. Dark has not had any communications with the FDA regurding the specific marketing approval requirements for DARE-FRT1 org March of Dimes Report Card, https://www.marchofdmes.org/mission/mortcard.appx CCS National Centre of Health Statistics, National Victa Statistics Reports, Briths: Final Data for 2018, Nov 27, 2018, https://www.cdc.gov/incheidata/mort/novrBR/ms

ttps://www.nicha.nin.gov/nealtn/topics/intertility/conditioninto/common accessed January 8, .

Harris Williams & Co. Fertility market overview. May 2015

Current products for delivery of progesterone for prevention of preterm birth, as well as luteal phase support in ART, are limited to daily vaginal or intramuscular injectable dosage forms, which have limitations in patient comfort, convenience, and outcomes.

The IVR is designed to deliver bioidentical progesterone continuously over a 14-day period and is being developed as a more convenient treatment option for the prevention of preterm birth (DARE-PTB1) and broader luteal phase support as part of an in vitro fertilization regimen (DARE-FRT1).

DARE-VVA1

Proprietary tamoxifen formulation for vaginal administration for vulvar and vaginal atrophy (VVA), a chronic condition characterized by pain during intercourse, vaginal dryness and irritation

Potential to be the first therapeutic specifically approved for treatment of VVA in patients with hormone-receptor positive (HR+) breast cancer.

•Approximately 3.8 million US women have a history of breast cancer; HR+ is the most common type.²

•Localized estrogen therapy for VVA may be contraindicated for women diagnosed with, or at risk of recurrence of, ER-positive and PRpositive breast cancer.

•VVA prevalence in postmenopausal breast cancer survivors is estimated at **42 to 70%.**³



Daré is developing this novel local application of tamoxifen to mitigate the symptoms of VVA for HR+ breast cancer patients, including women currently on anti-cancer therapy.

505(b)(2) candidate1

American Cancer Society, Breast Cancer Facts & Figures 2019-2020, https://www.sciencedirect.com/sciencer/acts-and-figures/breast-cancer-facts-and-figures/brea

DARE-VVA1 - Proof of Concept

This exploratory study² in four postmenopausal women diagnosed with VVA demonstrated that a self-administered vaginal suppository containing tamoxifen (20mg) dosed daily for one week and twice weekly for three months was effective in reducing vaginal pH and vaginal dryness.

Vaginal Tamoxifen	Enrollment (Baseline)	On Treatment (Month 3)	Paired Difference (Baseline vs. Month 3)
Median Vaginal pH Normal vaginal pH is usually less than 4.5. ²	7.1 range 6.5 to 7.5	5.0 range 5.0 to 5.2	-2.0 median range -2.5 to -1.5 Lower pH value is a measure of symptom relief
Vaginal Dryness Rated using a visual analogue scale (VAS) that ranged from: 0 = Not bothered by dryness 10 = Extremely bothered by dryness	8.0 range of 7.5 to 9.0	3.0 range 2.0 to 3.0	-5.5 median range -6.0 to -4.5 Decreased vaginal dryness is a measure of symptom relief

In addition, systemic absorption of tamoxifen was not significant:

•After 8 weeks of study treatment with vaginal tamoxifen, median plasma concentration of tamoxifen was 5.8 ng/ml, with a range of 1.0 to 10.0 ng/ml •In comparison, after 3 months of administration of 20mg, once-daily oral tamoxifen citrate (Nolvadex), 3 the average steady state plasma concentration of tamoxifen is 122 ng/ml with a range of 71 to 183 ng/ml

 Clin. Exp. Obstet. Gynecol. - ISSN: 0390-6663 XLVI, n. 2, 2019
 https://www.medicalnewstoday.com/articles/322537.php
 US Food and Drug Administration: "Drug Approval Package: No x (Tam

41

Phase 1/2 study¹ is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of DARE-VVA1 in postmenopausal participants with moderate to severe VVA and is being conducted by the Company's wholly owned subsidiary in Australia.

- The Phase 1/2 study will evaluate different doses of DARE-VVA1, a tamoxifen vaginal insert, in approximately 40 postmenopausal women with VVA, including a cohort of women with a history of breast cancer.
- The study is a randomized, multi-center, double-blind, parallel-arm, placebo-controlled, dose-ranging study that will evaluate the safety, tolerability, plasma pharmacokinetics (PK) and pharmacodynamics (PD) of DARE-VVA1.
- Eligible participants will be randomly allocated to one of five treatment groups (approximately 8 participants per group) that will evaluate four dose levels (1 mg, 5 mg, 10 mg, and 20 mg) and a placebo.
- Following a screening visit, DARE-VVA1 will be self-administered intravaginally once a day for the first two weeks, and then twice a week for the following six weeks for a total treatment period of 56 days.
- In each treatment group, participants will have serial blood sampling for PK analysis and undergo safety evaluations and preliminary assessments of effectiveness. Following the completion of the treatment period, participants will attend a safety follow-up visit.

The primary endpoints of the study will evaluate the **safety and tolerability** of DARE-VVA1 by vaginal administration and determine the plasma PK of DARE-VVA1 after intravaginal application.

Secondary endpoints will evaluate **preliminary efficacy** and PD of DARE-VVA1 in terms of most bothersome symptom and changes in vaginal cytology and pH.

https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-initiates-phase-12-clinical-study-dare-vva1

DARE-LARC1

Long-Acting, Reversible Personal Contraceptive System – levonorgestrel-releasing implant drug delivery system designed to store and precisely deliver hundreds of therapeutic doses over years that a woman can turn on and off herself, according to her own needs, without further healthcare provider intervention.



43



Financial Summary

Daré Financial Summary

Sept. 30, 2021 Financial Highlights:

•Cash provided from financing activities during 9 months ended 9/30/21: \$59.8 million (net)

•Cash and equivalents at 9/30/2021: \$45.6 million

Funding sources:

•Since inception, we have raised cash through sale of equity securities, M&A transactions, warrant and option exercises, nondilutive grants, and license fees

•We endeavor to be creative and opportunistic in seeking capital required to advance our candidates, and to be efficient in use of such capital

Updates Oct 1 – Nov 8, 2021:

•New ATM offering for up to \$50 million; SVB Leerink sales agent

CRADA: Paid \$1.25 million to NICHD toward the Ovaprene Phase 3 in accordance with payment schedule

•Common shares o/s: 76.6 million shares

•Warrants o/s: 1.6 million

DARING TO BE DIFFERENT® AND ADVANCING darébio PRODUCTS WOMEN WANT

